Published on in Vol 10, No 1 (2021): January

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/24414, first published .
Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study)

Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study)

Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study)

Journals

  1. Monterrosa-Castro Á, Prada-Tobar M, Monterrosa-Blanco A, Pérez-Romero D, Salas-Becerra C, Redondo-Mendoza V. Clinical suspicion of sarcopenic obesity and probable sarcopenic obesity in Colombian women with a history of surgical menopause: a cross-sectional study. Menopause 2022;29(6):664 View
  2. Terra L, Lee Meeuw Kjoe P, Agelink van Rentergem J, Beekman M, Heemskerk‐Gerritsen B, van Beurden M, Roeters van Lennep J, van Doorn H, de Hullu J, Mourits M, van Dorst E, Mom C, Slangen B, Gaarenstroom K, van der Kolk L, Collée J, Wevers M, Ausems M, van Engelen K, van de Beek I, Berger L, van Asperen C, Gomez Garcia E, Maas A, Hooning M, van der Wall E, van Leeuwen F, Schagen S. Long‐term effects of premenopausal risk‐reducing salpingo‐oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross‐sectional study. BJOG: An International Journal of Obstetrics & Gynaecology 2023;130(8):968 View
  3. KAZANCI F, ŞAHİN F. Jinekolojik Onkoloji Pratiğimizde Risk Azaltıcı Cerrahi Yönetimi Gerektiren Genetik Değişiklikler. Arşiv Kaynak Tarama Dergisi 2022;31(2):132 View
  4. Terra L, Beekman M, Engelhardt E, Heemskerk-Gerritsen B, van Beurden M, Roeters van Lennep J, van Doorn H, de Hullu J, Van Dorst E, Mom C, Slangen B, Gaarenstroom K, van der Kolk L, Collée J, Wevers M, Ausems M, Van Engelen K, van de Beek I, Berger L, van Asperen C, Gomez Garcia E, Maas A, Hooning M, Aaronson N, Mourits M, van Leeuwen F. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy. American Journal of Obstetrics and Gynecology 2023;228(4):440.e1 View
  5. Edaily S, Abdel-Razeq H. Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants. OncoTargets and Therapy 2022;Volume 15:815 View
  6. Mohr-Sasson A, Dadon T, Perri T, Rosenblat O, Friedman E, Korach J. Prophylactic salpingectomy with delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in BRCA1/2 mutation carriers: women's point of view. Menopause 2023;30(5):476 View
  7. Terra L, Heemskerk‐Gerritsen B, Beekman M, Engelhardt E, Mourits M, van Doorn H, de Hullu J, Mom C, Slangen B, Gaarenstroom K, van Beurden M, Roeters Van Lennep J, van Dorst E, van der Kolk L, Collée J, Wevers M, Ausems M, van Engelen K, van de Beek I, Berger L, van Asperen C, Gomez Garcia E, Maas A, Hooning M, Steensma A, van Leeuwen F. Urinary incontinence more than 15 years after premenopausal risk‐reducing salpingo‐oophorectomy: a multicentre cross‐sectional study. BJOG: An International Journal of Obstetrics & Gynaecology 2024;131(1):99 View
  8. Vermeulen R, van Altena J, Gaarenstroom K, van Beurden M, Kieffer J, Aaronson N, Kenter G, Korse C. Impact of risk-reducing salpingo-oophorectomy on lipid determinants, HbA1c and CRP. Climacteric 2023;26(5):489 View
  9. Greenwood A, Woodruff E, Nguyen C, Piper C, Clauset A, Brubaker L, Behbakht K, Bitler B. Early Ovarian Cancer Detection in the Age of Fallopian Tube Precursors. Obstetrics & Gynecology 2024;143(3):e63 View
  10. Gootzen T, Steenbeek M, van Bommel M, IntHout J, Kets C, Hermens R, de Hullu J. Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy. Familial Cancer 2024 View